A new kind of cell therapy is moving from the lab straight into patients’ bodies. Scientists have created tiny, targeted lipid nanoparticles that deliver CAR‑T instructions directly to a person’s own immune cells, turning them into cancer‑fighting soldiers inside the body. This “in‑vivo” approach skips the costly, time‑consuming step of growing engineered cells in a lab, making the treatment potentially affordable and widely available. Pre‑clinical work in human‑engineered mice and rhesus monkeys showed that a single injection can generate CAR‑T cells within hours, wiping out nearly 100 % of harmful B cells from blood and tissues. In leukemia models, some animals experienced complete tumor disappearance. Remarkably, the B‑cell population that returns after treatment is mostly harmless “naïve” cells, while the disease‑causing “memory” B cells stay eliminated – a phenomenon researchers call an “immune reset,” which could lead to long‑term remission for autoimmune patients. Building on these results, Capstan Therapeutics launched a Phase I clinical trial in June 2025 to test safety, dosing and durability in humans. If successful, this off‑the‑shelf, in‑body CAR‑T platform could turn a cutting‑edge, specialist therapy into a routine option for cancer and autoimmune diseases, ushering in a new era of precise, efficient and inclusive medicine.
Read morePromising Phase 1‑2 results have put Chinese researchers on the brink of a major win against pancreatic cancer, often called the “king of cancer.” If Phase 3 confirms the early data, new targeted medicines could soon be approved, giving patients fresh treatment options. One breakthrough focuses on the KRAS G12C mutation; scientists discovered that hitting two molecular pathways at once dramatically shrank tumors in lab studies. When they approached a drug maker that was developing those agents for lung cancer, the company pivoted to pancreatic trials, now entering Phase 3. The synergy between home‑grown drug firms and clinicians is also opening doors for immunotherapy. Pancreatic tumors are “cold” because dense scar tissue blocks immune cells, but the new targeted drugs are cracking that barrier, allowing checkpoint inhibitors to work more effectively. Radiation therapy is getting a boost, too. Heavy‑ion beams—thanks to their precise “Bragg peak” energy release—damage cancer cells while sparing surrounding tissue, and a decade of data backs their safety. Experts also stress everyday prevention: a high‑protein, vitamin‑rich, low‑sugar diet; quitting smoking and limiting alcohol; maintaining a healthy weight; managing stress and sleep. High‑risk individuals—those with a family history, new‑onset diabetes, long‑standing diabetes, chronic pancreatitis, or pancreatic cysts—should get an annual thin‑slice CT scan with contrast.
Read moreResearchers from Beijing Chaoyang Hospital have highlighted a wave of breakthrough results for bispecific antibodies (BsAbs) presented at the 2025 ASH meeting. These engineered drugs can bind two different proteins at once, helping the immune system hunt down stubborn multiple‑myeloma cells. In single‑agent trials, the BsAb LBL‑034 (targeting GPRC5D and CD3) produced response rates above 75% even in patients who had already failed five other therapies. Another antibody, Cevostamab, showed a 94% rate of deep, MRD‑negative remissions when used after CAR‑T treatment, and a 38‑43% overall response when given alone. Combination approaches are even more striking. The Phase 3 MajesTEC‑3 study found that adding teclistamab to the standard daratumumab regimen lifted three‑year progression‑free survival to 83% (versus 30% with standard care) and boosted complete‑response rates to over 80%. A dual‑BsAb regimen of talquetamab plus teclistamab achieved a 61% overall response in heavily pre‑treated patients, with especially strong results in those without extramedullary disease. Early‑line trials are also under way. Linvoseltamab given as first‑line therapy reached a 79% overall response and a 26% complete‑response rate, with most patients clearing detectable disease. While infection rates remain a concern, the data suggest BsAbs could soon become a cornerstone for both relapsed and newly diagnosed multiple myeloma, offering deeper, longer‑lasting remissions than many existing options.
Read more